Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties.
Anti-anxiety
Anxiety
Anxiogenic
Anxiolytic
CBD
Cannabinoid
Cannabis
THC
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
02 10 2020
02 10 2020
Historique:
received:
22
04
2020
accepted:
04
09
2020
entrez:
3
10
2020
pubmed:
4
10
2020
medline:
15
5
2021
Statut:
epublish
Résumé
Cannabis has been documented for use in alleviating anxiety. However, certain research has also shown that it can produce feelings of anxiety, panic, paranoia and psychosis. In humans, Δ To systematically review studies assessing cannabinoid interventions (e.g. THC or CBD or whole cannabis interventions) both in animals and humans, as well as recent epidemiological studies reporting on anxiolytic or anxiogenic effects from cannabis consumption. The articles selected for this review were identified up to January 2020 through searches in the electronic databases OVID MEDLINE, Cochrane Central Register of Controlled Trials, PubMed, and PsycINFO. Acute doses of CBD were found to reduce anxiety both in animals and humans, without having an anxiogenic effect at higher doses. Epidemiological studies tend to support an anxiolytic effect from the consumption of either CBD or THC, as well as whole plant cannabis. Conversely, the available human clinical studies demonstrate a common anxiogenic response to THC (especially at higher doses). Based on current data, cannabinoid therapies (containing primarily CBD) may provide a more suitable treatment for people with pre-existing anxiety or as a potential adjunctive role in managing anxiety or stress-related disorders. However, further research is needed to explore other cannabinoids and phytochemical constituents present in cannabis (e.g. terpenes) as anxiolytic interventions. Future clinical trials involving patients with anxiety disorders are warranted due to the small number of available human studies.
Sections du résumé
BACKGROUND
Cannabis has been documented for use in alleviating anxiety. However, certain research has also shown that it can produce feelings of anxiety, panic, paranoia and psychosis. In humans, Δ
OBJECTIVES
To systematically review studies assessing cannabinoid interventions (e.g. THC or CBD or whole cannabis interventions) both in animals and humans, as well as recent epidemiological studies reporting on anxiolytic or anxiogenic effects from cannabis consumption.
METHOD
The articles selected for this review were identified up to January 2020 through searches in the electronic databases OVID MEDLINE, Cochrane Central Register of Controlled Trials, PubMed, and PsycINFO.
RESULTS
Acute doses of CBD were found to reduce anxiety both in animals and humans, without having an anxiogenic effect at higher doses. Epidemiological studies tend to support an anxiolytic effect from the consumption of either CBD or THC, as well as whole plant cannabis. Conversely, the available human clinical studies demonstrate a common anxiogenic response to THC (especially at higher doses).
CONCLUSION
Based on current data, cannabinoid therapies (containing primarily CBD) may provide a more suitable treatment for people with pre-existing anxiety or as a potential adjunctive role in managing anxiety or stress-related disorders. However, further research is needed to explore other cannabinoids and phytochemical constituents present in cannabis (e.g. terpenes) as anxiolytic interventions. Future clinical trials involving patients with anxiety disorders are warranted due to the small number of available human studies.
Identifiants
pubmed: 33008420
doi: 10.1186/s12967-020-02518-2
pii: 10.1186/s12967-020-02518-2
pmc: PMC7531079
doi:
Substances chimiques
Anti-Anxiety Agents
0
Cannabidiol
19GBJ60SN5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
374Références
Cannabis Cannabinoid Res. 2016 Jul 01;1(1):166-175
pubmed: 28861492
Br J Psychiatry. 2010 Oct;197(4):285-90
pubmed: 20884951
Braz J Psychiatry. 2012 Jun;34 Suppl 1:S104-10
pubmed: 22729452
Curr Opin Psychiatry. 2020 Jan;33(1):1-7
pubmed: 31688192
Arch Gen Psychiatry. 2009 Jan;66(1):95-105
pubmed: 19124693
Biochem Pharmacol. 1972 Dec 15;21(24):3301-3
pubmed: 4405370
Med J Aust. 2018 Aug 3;209(5):211-216
pubmed: 30092752
Br J Sports Med. 2006 Jul;40 Suppl 1:i13-5
pubmed: 16799094
Br J Pharmacol. 2017 Oct;174(19):3242-3256
pubmed: 28268256
J Psychopharmacol. 2017 May;31(5):569-575
pubmed: 28372506
Res Commun Chem Pathol Pharmacol. 1973 May;5(3):621-6
pubmed: 4701259
Soc Sci Med. 2019 Jul;233:181-192
pubmed: 31207470
Psychopharmacology (Berl). 2017 Jul;234(14):2207-2217
pubmed: 28424834
Neuropsychopharmacology. 2011 May;36(6):1219-26
pubmed: 21307846
Dialogues Clin Neurosci. 2017 Sep;19(3):309-316
pubmed: 29302228
Psychopharmacology (Berl). 2002 Jun;161(4):331-9
pubmed: 12073159
J Neurosci. 2008 Mar 5;28(10):2313-9
pubmed: 18322078
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jul 2;38(1):88-96
pubmed: 22386778
Eur J Pharmacol. 2003 Feb 28;463(1-3):35-53
pubmed: 12600701
Front Behav Neurosci. 2019 Feb 20;13:32
pubmed: 30842732
Neuropsychopharmacology. 2007 Sep;32(9):2036-45
pubmed: 17287821
Cannabis Cannabinoid Res. 2016 Jun 01;1(1):131-138
pubmed: 28861489
Pharmacol Rev. 1986 Mar;38(1):1-20
pubmed: 3520605
J Pharmacol Exp Ther. 2006 Jul;318(1):304-11
pubmed: 16569753
Eur J Pharmacol. 2000 Mar 17;391(3):269-74
pubmed: 10729368
Cannabis Cannabinoid Res. 2017 Jun 01;2(1):139-154
pubmed: 28861514
Pharmacol Biochem Behav. 2003 Feb;74(3):649-56
pubmed: 12543231
J Pharm Pharmacol. 1972 Oct;24(10):833-4
pubmed: 4403988
Pharmacol Biochem Behav. 2005 Jun;81(2):331-42
pubmed: 15927244
Neuropsychopharmacology. 2008 Sep;33(10):2505-16
pubmed: 18185500
J Affect Disord. 2018 Aug 1;235:198-205
pubmed: 29656267
Behav Brain Res. 2006 Sep 25;172(2):240-9
pubmed: 16780969
BMJ. 2019 Apr 4;365:l1141
pubmed: 30948383
Int J Addict. 1978 Aug;13(6):947-59
pubmed: 730405
J Psychopharmacol. 2010 May;24(5):767-77
pubmed: 19406854
Psychopharmacology (Berl). 2016 Sep;233(18):3353-60
pubmed: 27438607
Int J Neuropsychopharmacol. 2010 Aug;13(7):861-76
pubmed: 19785914
Front Behav Neurosci. 2018 Mar 27;12:41
pubmed: 29636670
Br J Pharmacol. 1974 Feb;50(2):299-309
pubmed: 4609532
Neurotherapeutics. 2015 Oct;12(4):825-36
pubmed: 26341731
Psychiatry Res. 2003 May 1;118(1):1-8
pubmed: 12759155
Eur J Drug Metab Pharmacokinet. 2018 Feb;43(1):1-12
pubmed: 28534260
Front Behav Neurosci. 2019 May 07;13:94
pubmed: 31133833
Pharmacol Rev. 1971 Dec;23(4):371-80
pubmed: 4943951
Hum Psychopharmacol. 2009 Oct;24(7):515-23
pubmed: 19693792
Br J Addict Alcohol Other Drugs. 1971 Nov;66(3):185-7
pubmed: 5289284
Br J Pharmacol. 1978 Jan;62(1):19-24
pubmed: 563752
J Pharmacol Exp Ther. 1990 Jun;253(3):1002-9
pubmed: 2162942
J Psychopharmacol. 2013 Jan;27(1):19-27
pubmed: 23042808
Cannabis Cannabinoid Res. 2018 Jul 01;3(1):152-161
pubmed: 30014038
Science. 1954 Dec 24;120(3130):1045-52
pubmed: 13216221
Molecules. 2019 Aug 21;24(17):
pubmed: 31438532
Pharmacol Biochem Behav. 1998 Feb;59(2):347-52
pubmed: 9476980
Psychopharmacology (Berl). 2002 Dec;164(4):407-15
pubmed: 12457271
Pharmacol Biochem Behav. 1996 Mar;53(3):657-64
pubmed: 8866969
Pharmacol Biochem Behav. 2004 Mar;77(3):567-73
pubmed: 15006468
Br J Pharmacol. 2011 Aug;163(7):1344-64
pubmed: 21749363
Psychopharmacologia. 1976 May 28;47(2):141-8
pubmed: 1273209
Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:285-308
pubmed: 27618739
BMC Psychiatry. 2014 May 10;14:136
pubmed: 24884989
Behav Pharmacol. 2004 Feb;15(1):21-7
pubmed: 15075623
Aust N Z J Psychiatry. 1976 Dec;10(4):339-41
pubmed: 1071419
Psychopharmacology (Berl). 2007 May;191(4):867-77
pubmed: 17211649
Psychopharmacology (Berl). 1982;76(3):245-50
pubmed: 6285406
Eur J Pharmacol. 2007 Jan 26;555(2-3):156-63
pubmed: 17116299
Dtsch Arztebl Int. 2015 Apr 17;112(16):271-8
pubmed: 25939318
Recent Pat CNS Drug Discov. 2012 Apr 1;7(1):25-40
pubmed: 22280339
Psychopharmacology (Berl). 1976 Nov 10;50(2):159-63
pubmed: 826956
Mo Med. 2018 Nov-Dec;115(6):482-486
pubmed: 30643324
Neuropsychopharmacology. 2004 Aug;29(8):1558-72
pubmed: 15173844
Int J Neuropsychopharmacol. 2013 Nov;16(10):2273-84
pubmed: 23830148
Neuropsychopharmacology. 2012 Nov;37(12):2624-34
pubmed: 22850737
Br J Pharmacol. 2009 Jul;157(5):844-53
pubmed: 19422370
Eur Neuropsychopharmacol. 2003 Dec;13(6):401-10
pubmed: 14636956
J Psychopharmacol. 2011 Jan;25(1):121-30
pubmed: 20829306
J Dev Behav Pediatr. 2015 Feb-Mar;36(2):115-23
pubmed: 25650954
J Pain Res. 2017 May 02;10:989-998
pubmed: 28496355
Br J Pharmacol. 2002 Jan;135(2):564-78
pubmed: 11815392
Depress Anxiety. 2018 Jun;35(6):490-501
pubmed: 29486095
J Psychiatr Res. 2019 Apr;111:134-139
pubmed: 30738930
Eur J Pharmacol. 1974 Sep;28(1):172-7
pubmed: 4609777
BMJ. 2002 Nov 23;325(7374):1195-8
pubmed: 12446533
Pharmacol Biochem Behav. 2003 Jul;75(4):763-8
pubmed: 12957217
Psychopharmacology (Berl). 2002 Aug;163(1):111-7
pubmed: 12185408
Neuropharmacology. 2008 Jan;54(1):151-60
pubmed: 17692344
BMC Psychiatry. 2020 Jan 16;20(1):24
pubmed: 31948424
Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):17-35
pubmed: 30661105
Hum Psychopharmacol. 2004 Mar;19(2):97-101
pubmed: 14994319
Biol Pharm Bull. 2002 Dec;25(12):1629-33
pubmed: 12499653
Acta Pharmacol Toxicol (Copenh). 1980 Oct;47(4):308-17
pubmed: 6258385
Braz J Psychiatry. 2010 May;32 Suppl 1:S41-5
pubmed: 20512269
Pharmacol Biochem Behav. 2009 Aug;93(2):91-6
pubmed: 19393686
Pharmacol Biochem Behav. 2019 Jun;181:93-100
pubmed: 31063743
Br J Psychiatry. 2001 Feb;178:101-6
pubmed: 11157422